In this episode, Dr Virginia Kaklamani moderates a discussion with Dr Aditya Bardia and Dr Sarah Sammons answering audience questions on the latest data on the use of oral SERDs therapy, including how to incorporate this new class of therapy into treatment plans for patients with HR+/HER2- breast cancer.Presenters:Virginia Kaklamani, MD, DScProfessor of MedicineRuth McLean Bowman Bowers Chair in Breast Cancer Research and TreatmentA.B. Alexander Distinguished Chair in Oncology LeaderBreast Oncology ProgramUT Health San AntonioMD Anderson Cancer CenterSan Antonio, TexasAditya Bardia, MD, MPH, FASCOProfessor of MedicineGeffen School of Medicine at UCLADirector, Breast Oncology ProgramAssistant Chief (Translational Research)Division of Medical OncologyDirector of Translational Research IntegrationUCLA Health Jonsson Comprehensive Cancer CenterLos Angeles, CaliforniaSarah Sammons, MDAssistant Professor of MedicineDana-Farber Cancer Institute Harvard Medical SchoolBoston, Massachusetts Link to full program:https://bit.ly/46hLGcM

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related